How it Works

CELMoDs are large molecules that quickly degrade a specific set of proteins (called Ikaros and Aiolos). They are potent modulators of the cereblon E3 ligase complex, the main target of immunomodulatory agents (IMiDs), such as lenalidomide (Revlimid). They stimulate the immune system and kill malignant cells directly and more rapidly and aggressively than agents such as Pomalidomide.

How it’s Administered

CELMoDS are currently being given by intravenous injection (IV).

Who Should Take Iberdomide

Iberdomide is being tested in combination with dexamethasone and either daratumumab (Darzalex), bortezomib (Velcade), or carfilzomib (Kyprolis), showing efficacy and tolerability in patients with relapsed or refractory multiple myeloma.

Who Shouldn’t Take Iberdomide

• Patients who are allergic to Iberdomide.
• During pregnancy.

Most Common Side Effects of Taking Iberdomide Include:

• Fatigue
• Low White Blood Cell Count (Leukopenia or Neutropenia)
• Low Red Blood Cell Count (Anemia)
• Low Platelet Count (Thrombocytopenia)
• Diarrhea
• Constipation 
• Shortness of breath 
• Fever
• Nausea
• Rash
• Upper respiratory tract infection 

Commonly Being Tested With

• Daratumumab
• Ixazomib
• Isatuximab
• Carfilzomib
• Bortezomib
• Dexamethasone
• Cyclophosphamide

Learn more about your treatments in Cure Hub